(NASDAQ: ALZN) Alzamend Neuro's forecast annual earnings growth rate of N/A is not forecast to beat the US Biotechnology industry's average forecast earnings growth rate of 11.39%, and while it is not forecast to beat the US market's average forecast earnings growth rate of 31.51%.
Alzamend Neuro's earnings in 2026 is -$9,096,700.On average, 3 Wall Street analysts forecast ALZN's earnings for 2027 to be -$12,797,817, with the lowest ALZN earnings forecast at -$12,295,942, and the highest ALZN earnings forecast at -$13,174,224. On average, 3 Wall Street analysts forecast ALZN's earnings for 2028 to be -$14,963,602, with the lowest ALZN earnings forecast at -$14,376,794, and the highest ALZN earnings forecast at -$15,403,708.
In 2029, ALZN is forecast to generate -$4,233,124 in earnings, with the lowest earnings forecast at -$4,067,119 and the highest earnings forecast at -$4,357,628.